BIIB Biogen Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
17:15
Aug 04
Aug 04
CNBC
Earnings beat, breakout above $218 possible.
Biogen beat top- and bottom-line expectations with earnings coming in 18% above consensus and forward guidance raised. The stock has knocked on $218 multiple times; a clean close above that level would confirm a breakout. Traders can use $190 as support, investors can anchor to the 200-day at $183.
BIIB
Biogen Inc.
Long
1ST
—
—
12:00
Apr 21
Apr 21
ILTB Podcast
Alzheimer's drugs from Biogen and Lilly are promising.
Anti-amyloid medicines from Biogen and Eli Lilly can break up plaques in the brain and, if given early, could dramatically slow cognitive decline. Data expected later in 2025 may show that early intervention could reduce decline by 40-50% or more.
BIIB
Biogen Inc.
Long
1ST
—
—
About BIIB Investor Commentary
Across the available history and selected sources, Buzzberg tracks BIIB (Biogen Inc.) across 16 sources: 11 bullish vs 0 bearish calls from 18 authors. Historical directional balance: 38% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 29 total trade ideas tracked. Latest voices: Josh Brown, Alex Karnal, Jim Cramer.